Heijke, Rebecca
Björk, Mathilda http://orcid.org/0000-0002-1607-187X
Thyberg, Ingrid http://orcid.org/0000-0003-0102-738X
Kastbom, Alf http://orcid.org/0000-0001-7187-1477
McDonald, Laura http://orcid.org/0000-0002-7087-6548
Sjöwall, Christopher http://orcid.org/0000-0003-0900-2048
Funding for this research was provided by:
Bristol-Myers Squibb
Linköping University
Article History
Received: 5 June 2021
Revised: 1 October 2021
Accepted: 1 November 2021
First Online: 27 November 2021
Declarations
:
: The study met ethical standards for human and animal rights, and the protocols were approved by the regional ethical review board in Linköping (Decision No. M168–05 and M75–08/2008).
: All SLE patients from the <i>Clinical Lupus Register in Northeastern Gothia</i>, Sweden (KLURING), gave oral and written informed consent, and the patient anonymity was preserved. Patients with RA were included from the observational <i>2nd Timely Interventions in Early RA</i> study (TIRA-2; 2006–2009), and all participating patients gave their written informed consent.
: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
: Rebecca Heijke, Mathilda Björk, Ingrid Thyberg, and Christopher Sjöwall declare that they have no conflict of interest. Alf Kastbom has been a consultant for Bristol Myers Squibb, Pfizer, Roche, and UCB and is a previous employee of Sanofi. Laura McDonald is an employee and shareholder of Bristol Myers Squibb.